MedTrace Logo

Surveillance of Kaletra in Korean Patients

NCT01083173 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 595

Last updated 2016-02-22

Study results available
· View outcomes & findings →

Summary

This single-arm, multi-center, Post-Marketing Surveillance study of Kaletra (lopinavir/ritonavir) was conducted in accordance with the approved Korean product labeling in participants 2 years of age and older with human immunodeficiency virus type 1 (HIV-1) infection.

Conditions

  • HIV-1 Infection

Sponsors & Collaborators

  • AbbVie (prior sponsor, Abbott)

    lead INDUSTRY

Principal Investigators

  • SoRa Lee, MD · AbbVie Ltd.

Eligibility

Min Age
2 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2014-10-31
Completion
2014-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01083173 on ClinicalTrials.gov